Biotech Startups

1 investor

Ventora Medical develops a neonatal airway pressure monitoring device for clinicians managing non-invasive respiratory support in newborn patients. The device provides continuous, accurate measurement of airway pressure delivered by CPAP and high-flow nasal cannula systems.

1 investor

1 investor

VeraMorph is a drug delivery company that has developed a proprietary oral drug delivery platform used to improve solubility and clinical translation of poorly soluble compounds. It works with pharmaceutical companies and is building a portfolio of clinically differentiated oral versions of approved drugs.

1 investor

Veranova is a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), including highly potent APIs, drug linkers, and complex small molecule chemistry. It provides process and analytical development, solid form sciences, and scale-up to commercial manufacturing for pharmaceutical companies developing small molecule drugs.

1 investor

Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.

1 investor

Verb Biotics develops function-first microbiome ingredients, including probiotics and postbiotics, aimed at improving human and companion animal health. It supplies these biotic ingredients to food, beverage, and supplement brands targeting health states such as stress, mood, sleep, healthy aging, women's health, and metabolic health.

1 investor

Verdel Instruments develops total correlation mass spectrometry (TOC-MS), a method using stored waveform ion radius modulation (SWIM) to generate MS/MS data for every analyte in a complex mixture. It sells upgrade kits that add this multi-dimensional capability to existing quadrupole-time of flight mass spectrometers, with optional ultraviolet photodissociation modifications.

1 investor

VERDOT designs and manufactures downstream purification solutions for biopharmaceutical and biotechnology companies to enable the production of therapeutic biologics. The company has over 70 years of manufacturing experience, with more than three decades focused on bioprocessing.

1 investor

Verge Labs builds all-in-human foundation models trained on a proprietary multimodal brain dataset to predict drug targets, patient response, and biomarkers for neurological diseases. Its platform serves drug developers working on neurodegenerative conditions, supporting target discovery, patient stratification, and the design of smaller, lower-risk clinical trials.

1 investor

Verge Labs develops vBx-1.0, a multi-modal biological foundation model trained on proprietary patient data that reasons about neurological disease at the patient level by integrating brain biology, blood biomarkers, and clinical trajectories. The model enables researchers and clinicians to predict patient disease progression and treatment response while deriving virtual brain biopsies from more accessible biological measurements.

1 investor

Vericel manufactures and markets advanced cell therapy products for sports medicine and severe burn care, and holds an exclusive North American license for NexoBrid. The company serves the U.S. medical market in these therapeutic areas.

1 investor

Verix Health develops a platform of steerable surgical devices designed to reach and target cancer in hard-to-access areas of the body, intended for interventional oncologists and their patients.

1 investor

Vernal Biosciences is an mRNA contract development and manufacturing organization (CDMO) that produces high-quality mRNA for research and therapeutic development. The company serves researchers and biotech companies seeking reliable mRNA supply for drug discovery and clinical applications.

1 investor

Vero BioScience develops a blood-based proteomic test that measures organ-specific protein signatures to assess the biological age of individual organs and detect early signs of age-related disease. The company targets individuals seeking predictive health insights and preventive medicine interventions based on technology developed at Stanford.

1 investor

VEROVACCiNES develops recombinant vaccines for animal health using engineered strains of the yeast Kluyveromyces lactis that express one or more antigens. The company offers a unified vaccine platform intended to produce tailored veterinary vaccines quickly in response to changing pathogens.

1 investor

Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.

1 investor

Vertex Ventures China (祥峰投资中国基金) is an early-stage venture capital firm backed by Singapore's Temasek Holdings, investing in high-growth technology and biomedical startups in China across robotics, AI, semiconductors, advanced manufacturing, carbon neutrality, new materials, pharmaceuticals, medical devices, and commercial space. Operating in China since 2009 with offices in Beijing, Shanghai, Shenzhen, and Singapore, it manages roughly 20 billion RMB across multiple USD and RMB funds.

1 investor

Vesper is a venture builder in biotechnology that spins out companies in human health and agriculture from early-stage research. The company combines capital deployment, IP structuring, and operational support to commercialize scientific innovations.

1 investor

Vetbiolix develops first-in-class therapeutic drugs for companion animals, specifically targeting osteoarthritis, periodontitis, and gut motility disorders in dogs and cats. The company adapts promising drug candidates from human clinical development stages to the veterinary market.

1 investor

A veterinary pharmaceutical company developing Rabacfosadine, an acyclic nucleotide analogue for treating lymphoma in dogs and cats.

1 investor

VETSTEM develops regenerative cell therapies based on multipotent mesenchymal stem cells (MSCs) and high-bioavailability pharmaceutical products for treating diseases in pets. The company operates in veterinary biotech, applying molecular-cell technologies and pharmaceutical chemistry to animal health.

1 investor

N&E Innovations develops ViKANG, a natural antibacterial agent made from food waste, certified to eliminate bacteria and viruses for use in disinfectants, water treatment, and food-grade plastics. The company operates with a circular economy model to reduce carbon emissions and environmental impact while addressing global health challenges.

1 investor

Vial develops first- and best-in-class biologic therapeutics — including RNA, antibody, and small molecule programs — for immunology and inflammatory disorders, using AI-driven target discovery and molecule design. It evaluates its programs through an in-house clinical trial platform.

1 investor